ACADIA Pharmaceuticals Shares Sold by Intech Investment Management

Institutional investor decreased position in biopharmaceutical company by 36% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Intech Investment Management LLC decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 36.0% during the 3rd quarter, according to the company's SEC filing. The institutional investor owned 48,250 shares of the biopharmaceutical company's stock worth $1,030,000 at the end of the quarter.

Why it matters

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders. The decrease in Intech's position in the company could signal a shift in investor sentiment or portfolio strategy, which could impact the stock price and the company's future prospects.

The details

According to the filing, Intech Investment Management sold 27,160 ACADIA Pharmaceuticals shares during the 3rd quarter, reducing its total position to 48,250 shares. Other institutional investors and hedge funds have also made changes to their ACADIA Pharmaceuticals holdings, with some increasing and others decreasing their positions. The company's flagship product is NUPLAZID, which is used to treat Parkinson's disease psychosis.

  • Intech Investment Management decreased its ACADIA Pharmaceuticals position during the 3rd quarter of 2026.

The players

Intech Investment Management LLC

An institutional investor that decreased its position in ACADIA Pharmaceuticals by 36% in the 3rd quarter.

ACADIA Pharmaceuticals Inc.

A biopharmaceutical company focused on developing therapies for central nervous system disorders, including Parkinson's disease psychosis.

Got photos? Submit your photos here. ›

The takeaway

The decrease in Intech Investment Management's position in ACADIA Pharmaceuticals could signal a shift in investor sentiment towards the biopharmaceutical company, which may impact the stock price and the company's future prospects. However, other institutional investors have made changes to their ACADIA Pharmaceuticals holdings, both increasing and decreasing their positions, indicating a mixed outlook on the company's performance.